Nanocrystalline cerium dioxide efficacy for gastrointestinal motility: Potential for prokinetic treatment and prevention in elderly

EPMA Journal

Volumn 6, Issue 1, 2015, Pages

  Yefimenko, Olena Y ^a   Savchenko, Yuliya O ^a   Falalyeyeva, Tetyana M ^a   Beregova, Tetyana V ^a   Zholobak, Nadiya M ^b   Spivak, Mykola Y ^b,c   Shcherbakov, Oleksandr B ^b   Bubnov, Rostyslav V ^b,d  

^a TARAS SHEVCHENKO NATIONAL UNIVERSITY OF KYIV   (Ukraine)

^b ZABOLOTNY INSTITUTE OF MICROBIOLOGY AND VIROLOGY   (Ukraine)

^c LCL 'DIAPROF'   (Ukraine)

^d Clinical Hospital 'Pheophania' of State Affairs Department   (Ukraine)

Author keywords

Colon; CRC prevention; Gastrointestinal cancer prevention; Gastrointestinal motility; Nanocrystalline cerium dioxide; Personalized medicine; Predictive; Preventive; Prokinetic; Rat model; Smooth muscle; Stomach

Indexed keywords

DIGESTIVE TRACT SPASMOLYTIC AGENT; NANOCRYSTALLINE CERIUM DIOXIDE; UNCLASSIFIED DRUG;

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON MOTILITY; CONTROLLED STUDY; DRUG EFFICACY; GASTROINTESTINAL MOTILITY DISORDER; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RAT; SMOOTH MUSCLE CONTRACTILITY; STOMACH MOTILITY;

EID: 84927762202     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1186/s13167-015-0029-z     Document Type: Article

References (69)

1. Talley NJ, O'Keefe EA, Zinsmeister AR, Melton LJ. Prevalence of gastrointestinal symptoms in the elderly: a population-based study. Gastroenterology 1992, 102(3):895-901. 1537525.
2. Madsen JL, Graff J. Effects of ageing on gastrointestinal motor function. Age Ageing 2004, 33(2):154-9. 10.1093/ageing/afh040, 14960431.
3. Tayyem RF, Shehadeh IN, Abumweis SS. Physical inactivity, water intake and constipation as risk factors for colorectal cancer among adults in Jordan. Asian Pac J Cancer Prev 2013, 14(9):5207-12. 10.7314/APJCP.2013.14.9.5207, 24175802.
4. Hagan S, Orr MC, Doyle B. Targeted therapies in colorectal cancer-an integrative view by PPPM. EPMA J 2013, 4(1):3. 10.1186/1878-5085-4-3, 23356214.
5. Golubnitschaja O, Costigliola V. General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised medicine. EPMA J 2012, 3:14. 10.1186/1878-5085-3-14, 23116135.
6. Senna and its rational use. Pharmacology 1992, 44:1-52.
7. Urganci N, Akyildiz B, Polat TB. A comparative study: the efficacy of liquid paraffin and lactulose in management of chronic functional constipation. Pediatr Int 2005, 47(1):15-9. 10.1111/j.1442-200x.2004.02001.x, 15693860.
8. Ewe K, Ueberschaer B, Press AG, Kurreck C, Klump M. Effect of lactose, lactulose and bisacodyl on gastrointestinal transit studied by metal detector. Aliment Pharmacol Ther 1995, 9(1):69-73. 10.1111/j.1365-2036.1995.tb00354.x, 7766747.
9. Bayliss WM, Starling EH. The movements and innervation of the small intestine. J Physiol 1899, 24(2):99-143. May 11, 10.1113/jphysiol.1899.sp000752, 16992487.
10. Zádori ZS, Fehér T, Al-Khrasani M, Lackó E, Tóth VE, Brancati SB, et al. Imidazoline versus alpha2-adrenoceptors in the control of gastric motility in mice. Eur J Pharmacol 2013, 705(1-3):61-7. 10.1016/j.ejphar.2013.02.043, 23499689.
11. Burdyga V, Kosterin SA. Kinetic analysis of smooth muscle relaxation. Gen Physiol Biophys 1991, 10(6):589-98. 1802780.
12. Ivanova OS, Shekynova TO, Ivanov V, Scherbakov T, Popov T. One-step synthesis of colloidal solutions of cerium dioxide for biomedical applications. Dokl Akadem nayk 2011, 437(5):638-41. [Russian].
13. Zholobak NM, Ivanov VK, Shcherbakov AB, Shaporev AS, Polezhaeva OS, Baranchikov AY, et al. UV-shielding property, photocatalytic activity and photocytotoxicity of ceria colloid solutions. J Photochem Photobiol B 2011, 102(1):32-8. 10.1016/j.jphotobiol.2010.09.002, 20926307.
14. TyurinYuN T. Distribution associated with normal 1998, Moscow, Infra.
15. Kuriyama H, Kitamura K, Itoh T, Inoue R. Physiological features of visceral smooth muscle cells, with special reference to receptors and ion channels. Physiol Rev 1998, 78(3):811-920. 9674696.
16. Ibitayo AI, Sladick J, Tuteja S, Louis-Jacques O, Yamada H, Groblewski G, et al. HSP27 in signal transduction and association with contractile proteins in smooth muscle cells. Am J Physiol 1999, 277(2 Pt 1):G445-54. 10444459.
17. Roberts D, Gelperin D, Wiley JW. Evidence for age-associated reduction in acetylcholine release and smooth muscle response in the rat colon. Am J Physiol 1994, 267(4 Pt 1):G515-22. 7943316.
18. Xiong Z, Sperelakis N, Noffsinger A, Fenoglio-Preiser C. Potassium currents in rat colonic smooth muscle cells and changes during development and aging. Pflugers Arch 1995, 430(4):563-72. 10.1007/BF00373893, 7491283.
19. Abalo R, Vera G, Rivera AJ, Martín MI. Age-related changes in the gastrointestinal tract: a functional and immunohistochemical study in guinea-pig ileum. Life Sci 2007, 80(26):2436-45. 10.1016/j.lfs.2007.04.004, 17509618.
20. Zholobak NM, Sherbakov AB, Babenko LS, Bogorad-Kobelska OS, Bubnov RV, Spivak MY, et al. The perspectives of biomedical application of the nanoceria. EPMA J 2014, 5(1):A136. 10.1186/1878-5085-5-S1-A136.
21. Spivak MY, Bubnov RV, Yemets IM, Lazarenko LM, Tymoshok NO, Ulberg ZR. Gold nanoparticles - the theranostic challenge for PPPM: nanocardiology application. EPMA J 2013, 4(1):18. 10.1186/1878-5085-4-18, 23800174.
22. Spivak MY, Bubnov RV, Yemets IM, Lazarenko LM, Tymoshok NO, Ulberg ZR. Development and testing of gold nanoparticles for drug delivery and treatment of heart failure: a theranostic potential for PPP cardiology. EPMA J 2013, 4(1):20. 10.1186/1878-5085-4-20, 23889805.
23. Maslowski KM, Mackay CR. Diet, gut microbiota and immune responses. Nat Immunol 2011, 12(1):5-9. doi: 10.1038/ni0111-5, 10.1038/ni0111-5, 21169997.
24. Strachan DP. Hay fever, hygiene, and household size. BMJ 1989, 299:1259-60. 10.1136/bmj.299.6710.1259, 2513902.
25. Savcheniuk OA, Virchenko OV, Falalyeyeva TM, Beregova Tetyana V, Babenko LP, Lazarenko LM, et al. The efficacy of probiotics for monosodium glutamate-induced obesity: dietology concerns and opportunities for prevention. EPMA J 2014, 5:2. 10.1186/1878-5085-5-2, 24410812.
26. Toda N, Okamura T. Obesity impairs vasodilatation and blood flow increase mediated by endothelial nitric oxide: an overview. J Clin Pharmacol 2013, 53(12):1228-39. doi:10.1002/jcph.179, 10.1002/jcph.179, 24030923.
27. Chatsuriyawong S, Gozal D, Kheirandish-Gozal L, Bhattacharjee R, Khalyfa AA, Wang Y, et al. Genetic variance in nitric oxide synthase and endothelin genes among children with and without endothelial dysfunction. J Transl Med 2013, 11:227. 10.1186/1479-5876-11-227, 24063765.
28. Leung TF, Liu EK, Tang NL, Ko FW, Li CY, Lam CW, et al. Nitric oxide synthase polymorphisms and asthma phenotypes in Chinese children. Clin Exp Allergy 2005, 35(10):1288-94. 10.1111/j.1365-2222.2005.02342.x, 16238787.
29. Freedman BI, Yu H, Anderson PJ, Roh BH, Rich SS, Bowden DW. Genetic analysis of nitric oxide and endothelin in end-stage renal disease. Nephrol Dial Transplant 2000, 15(11):1794-800. 10.1093/ndt/15.11.1794, 11071967.
30. Meyer MR, Fredette NC, Barton M, Prossnitz ER. Regulation of vascular smooth muscle tone by adipose-derived contracting factor. PLoS One 2013, 8(11):e79245. 10.1371/journal.pone.0079245, 24244459.
31. Hiromura T, Nishioka T, Nishioka S, Ikeda H, Tomita K. Reflux in the left ovarian vein: analysis of MDCT findings in asymptomatic women. AJR Am J Roentgenol 2004, 183(5):1411-5. 10.2214/ajr.183.5.1831411, 15505313.
32. Bubnov RV, et al. Ultrasonography diagnostic capability for mesenteric vascular disorders. Gut 2011, 60(Suppl 3):A104.
33. Yeghiazaryan K, Flammer J, Golubnitschaja O. Predictive molecular profiling in blood of healthy vasospastic individuals: clue to targeted prevention as personalised medicine to effective costs. EPMA J 2010, 1(2):263-72. 10.1007/s13167-010-0032-3, 23199064.
34. Lushchyk UB, Novytskyy VV, Babii IP, Lushchyk NG, Riabets LS. Predictive and preventive strategies to advance the treatments of cardiovascular and cerebrovascular diseases: the Ukrainian context. EPMA J 2012, 3(1):12. 10.1186/1878-5085-3-12, 23083430.
35. Bubnov RV. Evidence-based pain management: is the concept of integrative medicine applicable?. EPMA J 2012, 3(1):13. 10.1186/1878-5085-3-13, 23088743.
36. Konieczka K, Ritch R, Traverso CE, Kim DM, Kook MS, Gallino A, et al. Flammer syndrome. EPMA J 2014, 5:11. 10.1186/1878-5085-5-11, 25075228.
37. Furness JB, Callaghan BP, Rivera LR, Cho HJ. The enteric nervous system and gastrointestinal innervation: integrated local and central control. Adv Exp Med Biol 2014, 817:39-71. 10.1007/978-1-4939-0897-4_3, 24997029.
38. Burzynski G, Shepherd IT, Enomoto H. Genetic model system studies of the development of the enteric nervous system, gut motility and Hirschsprung's disease. Neurogastroenterol Motil 2009, 21:113-27. 10.1111/j.1365-2982.2008.01256.x, 19215589.
39. Wafai L, Taher M, Jovanovska V, Bornstein JC, Dass CR, Nurgali K. Effects of oxaliplatin on mouse myenteric neurons and colonic motility. Front Neurosci 2013, 7:30. 10.3389/fnins.2013.00030, 23486839.
40. Linden DR, Sharkey KA, Mawe GM. Enhanced excitability of myenteric AH neurones in the inflamed guinea-pig distal colon. J Physiol 2003, 547:589-601. doi:10.1113/jphysiol.2002.035147, 10.1113/jphysiol.2002.035147, 12562910.
41. Lomax AE, O'Hara JR, Hyland NP, Mawe GM, Sharkey KA. Persistent alterations to enteric neural signaling in the guinea pig colon following the resolution of colitis. Am J Physiol Gastrointest Liver Physiol 2007, 292:G482-91. 10.1152/ajpgi.00355.2006, 17008554.
42. Demir IE, Friess H, Ceyhan GO. Nerve-cancer interactions in the stromal biology of pancreatic cancer. Front Physiol 2012, 3:97. 10.3389/fphys.2012.00097, 22529816.
43. Ceyhan GO, Demir IE, Altintas B, Rauch U, Thiel G, Müller MW, et al. Neural invasion in pancreatic cancer: a mutual tropism between neurons and cancer cells. Biochem Biophys Res Commun 2008, 374(3):442-7. 10.1016/j.bbrc.2008.07.035, 18640096.
44. Ceyhan GO, Demir IE, Rauch U, Bergmann F, Muller MW, Buchler MW, et al. Pancreatic neuropathy results in " neural remodeling" and altered pancreatic innervation in chronic pancreatitis and pancreatic cancer. Am J Gastroenterol 2009, 104:2555-256510. doi: 1038/ajg.2009.380, 10.1038/ajg.2009.380, 19568227.
45. Ceyhan GO, Demir IE, Altintas B, Rauch U, Thiel G, Muller MW, et al. Neural invasion in pancreatic cancer: a mutual tropism between neurons and cancer cells. Biochem Biophys Res Commun 2008, 374:442-44710. doi:1016/j.bbrc.2008.07.035, 10.1016/j.bbrc.2008.07.035, 18640096.
46. Ayala GE, Wheeler TM, Shine HD, Schmelz M, Frolov A, Chakraborty S, et al. In vitro dorsal root ganglia and human prostate cell line interaction: redefining perineural invasion in prostate cancer. Prostate 2001, 49(3):213-23. 10.1002/pros.1137, 11746267.
47. Voss MJ, Entschladen F. Tumor interactions with soluble factors and the nervous system. Cell Commun Signal 2010, 8:21. 10.1186/1478-811X-8-21, 20822525.
48. Tilan J, Kitlinska J. Sympathetic neurotransmitters and tumor angiogenesis-link between stress and cancer progression. J Oncol 2010, 2010:539706. doi:10.1155/2010/539706, 10.1155/2010/539706, 20508839.
49. Imani Fooladi AA, Mahmoodzadeh Hosseini H, Nourani MR, Khani S, Alavian SM. Probiotic as a novel treatment strategy against liver disease. Hepa Month 2013, 13(2):e7521. doi:10.5812/hepatmon.7521.
50. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med 2009, 60:355-66. 10.1146/annurev.med.60.042307.110802, 19630576.
51. Khan WI, Ghia JE. Gut hormones: emerging role in immune activation and inflammation. Clin Exp Immunol 2010, 161:19-27. 20408856.
52. Li Z, Chalazonitis A, Huang YY, Mann JJ, Margolis KG, Yang QM, et al. Essential roles of enteric neuronal serotonin in gastrointestinal motility and the development/survival of enteric dopaminergic neurons. J Neurosci 2011, 31:8998-9009. 10.1523/JNEUROSCI.6684-10.2011, 21677183.
53. Crane JD, Palanivel R, Mottillo EP, Bujak AL, Wang H4, Ford RJ, Collins A, Blümer RM, Fullerton MD, Yabut JM, Kim JJ, Ghia JE, Hamza SM,Morrison KM, Schertzer JD, Dyck JR, Khan WI, Steinberg GR: Inhibiting peripheral serotonin synthesis reduces obesity and metabolic dysfunction by promoting brown adipose tissue thermogenesis. Nat Med. 2014 Dec 8. doi:10.1038/nm.3766. [Epub ahead of print]..
54. Liu H, Mantyh PW, Basbaum AI. NMDA-receptor regulation of substance P release from primary afferent nociceptors. Nature 1997, 386(6626):721-4. 10.1038/386721a0, 9109489.
55. Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994, 37(11):1593-601. 10.1002/art.1780371106, 7526868.
56. De Stefano R, Selvi E, Villanova M, Frati E, Manganelli S, Franceschini E, et al. Image analysis quantification of substance P immunoreactivity in the trapezius muscle of patients with fibromyalgia and myofascial pain syndrome. J Rheumatol 2000, 27(12):2906-10. 11128684.
57. Stark D, van Hal S, Marriott D, Ellis J, Harkness J. Irritable bowel syndrome: a review on the role of intestinal protozoa and the importance of their detection and diagnosis. Int J Parasitol 2007, 37(1):11-20. 10.1016/j.ijpara.2006.09.009, 17070814.
58. Scheurer U, Drack E, Halter F. Substance P activates rat colonic motility via excitatory and inhibitory neural pathways and direct action on muscles. J Pharmacol Exper Therapeutics 1994, 271(1):7-13.
59. Bossaller C, Reither K, Hehlert-Friedrich C, Auch-Schwelk W, Graf K, Gräfe M, et al. In vivo measurement of endothelium-dependent vasodilation with substance P in man. Herz 1992, 17(5):284-90. 1282120.
60. Mihaylov S, Stark C, McColl E, Steen N, Vanoli A, Rubin G, et al. Stepped treatment of older adults on laxatives. The STOOL trial. Health Technol Assess 2008, 12(13):139. iii-iv, ix, 10.3310/hta12130.
61. Gordon M, Naidoo K, Akobeng AK, Thomas AG. Cochrane Review: Osmotic and stimulant laxatives for the management of childhood constipation (review). Evid Based Child Health 2013, 8(1):57-109. 10.1002/ebch.1893, 23878124.
62. Jones MP, Talley NJ, Nuyts G, Dubois D. Lack of objective evidence of efficacy of laxatives in chronic constipation. Dig Dis Sci 2002, 47(10):2222-30. 10.1023/A:1020131126397, 12395895.
63. Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut 2011, 60(2):209-18. 10.1136/gut.2010.227132, 21205879.
64. Petticrew M, Watt I, Sheldon T. Systematic review of the effectiveness of laxatives in the elderly. Health Technol Assess 1997, 1(13):1-52.
65. Ramkumar D, Rao SSC. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol 2005, 100:936e71. 10.1111/j.1572-0241.2005.40925.x.
66. World Gastroenterology Organisation practice guidelines: constipation. http://www.worldgastroenterology.org/assets/downloads/en/pdf/guidelines/05_constipation.pdf..
67. Tramonte SM, Brand MB, Mulrow CD, Amato MG, O'Keefe ME, Ramirez G. The treatment of chronic constipation in adults: a systematic review. J Gen Intern Med 1999, 12:15e24.
68. Belsey JD, Geraint M, Dixon TA. Systematic review and meta-analysis: polyethylene glycol in adults with non-organic constipation. Int J Clin Pract 2010, 64:944e55. 10.1111/j.1742-1241.2010.02397.x.
69. Gorkom BAPV, De Vries EGE. Review article: anthranoid laxatives and their potential carcinogenic effects. Aliment Pharmacol Ther 1999, 13(4):443-52. 10.1046/j.1365-2036.1999.00468.x, 10215727.